OLIVER W contact PRESS

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
    Franz Buchegger
    Department of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland
    EJNMMI Res 1:7. 2011
  2. pmc Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
    Oliver W Press
    Fred Hutchinson Cancer Research Center, D3 190, 1100 Fairview Ave, Seattle, WA 98109, USA
    J Clin Oncol 31:314-20. 2013
  3. doi request reprint Effect of cationic side-chains on intracellular delivery and cytotoxicity of pH sensitive polymer-doxorubicin nanocarriers
    Chen Fang
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Nanoscale 4:7012-20. 2012
  4. ncbi request reprint A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
    Oliver W Press
    Fred Hutchinson Cancer Research Center, D3 190, 1100 Fairview Ave, Seattle, WA 98109, USA
    Blood 102:1606-12. 2003
  5. ncbi request reprint Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246
    O W Press
    University of Washington Cancer Center, USA
    J Clin Oncol 16:574-8. 1998
  6. ncbi request reprint A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
    O W Press
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Blood 98:2535-43. 2001
  7. ncbi request reprint Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911
    Oliver W Press
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 24:4143-9. 2006
  8. ncbi request reprint The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation
    Grant E Keeney
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA
    Leuk Lymphoma 48:1961-7. 2007
  9. ncbi request reprint Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies
    Steven I Park
    Department of Medicine, Division of Hematology, University of Washington, USA
    Curr Opin Hematol 14:632-8. 2007
  10. ncbi request reprint Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007

Research Grants

  1. Bispecific Antibody Engineering for AML RIT
    OLIVER W contact PRESS; Fiscal Year: 2010
  2. PRETARGETING RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 2006
  3. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver Press; Fiscal Year: 2007
  4. Anti-CD20 CTL for Therapy of Mantle Cell Lymphoma
    Oliver Press; Fiscal Year: 2007
  5. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver W Press; Fiscal Year: 2010
  6. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver W Press; Fiscal Year: 2010
  7. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 2001
  8. Chimeric Anti CD20 T Cell Receptors for Lymphoma Therapy
    Oliver Press; Fiscal Year: 2003
  9. INTRACELLULAR TRAFFICKING OF IMMUNOTOXINS
    Oliver Press; Fiscal Year: 2003

Collaborators

Detail Information

Publications48

  1. pmc Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
    Franz Buchegger
    Department of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland
    EJNMMI Res 1:7. 2011
    ..We now raise the question whether both RIT consolidation and rituximab maintenance should be used together aiming to augment the results achievable with R-chemotherapy...
  2. pmc Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
    Oliver W Press
    Fred Hutchinson Cancer Research Center, D3 190, 1100 Fairview Ave, Seattle, WA 98109, USA
    J Clin Oncol 31:314-20. 2013
    ....
  3. doi request reprint Effect of cationic side-chains on intracellular delivery and cytotoxicity of pH sensitive polymer-doxorubicin nanocarriers
    Chen Fang
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Nanoscale 4:7012-20. 2012
    ..Thus, it is a crucial factor to be considered in the design of novel carriers for intracellular drug delivery...
  4. ncbi request reprint A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
    Oliver W Press
    Fred Hutchinson Cancer Research Center, D3 190, 1100 Fairview Ave, Seattle, WA 98109, USA
    Blood 102:1606-12. 2003
    ..This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016)...
  5. ncbi request reprint Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246
    O W Press
    University of Washington Cancer Center, USA
    J Clin Oncol 16:574-8. 1998
    ....
  6. ncbi request reprint A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
    O W Press
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Blood 98:2535-43. 2001
    ..These data suggest that anti-CD20 pretargeting shows great promise for improving current therapeutic options for B-cell lymphomas and warrants further preclinical and clinical testing...
  7. ncbi request reprint Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911
    Oliver W Press
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 24:4143-9. 2006
    ..This study was performed to determine the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab...
  8. ncbi request reprint The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation
    Grant E Keeney
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA
    Leuk Lymphoma 48:1961-7. 2007
    ..82, p = 0.03) after adjusting for FLIPI. These data suggest that the FLIPI and select non-FLIPI factors after adjustment for the FLIPI are associated with survival in FL patients undergoing ASCT...
  9. ncbi request reprint Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies
    Steven I Park
    Department of Medicine, Division of Hematology, University of Washington, USA
    Curr Opin Hematol 14:632-8. 2007
    ..This review will present the latest information on radioimmunotherapy for treatment of hematologic malignancies in various clinical settings and assess its long-term safety profile...
  10. ncbi request reprint Pretargeted radioimmunotherapy for B-cell lymphomas
    Damian J Green
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 13:5598s-5603s. 2007
    ..We are optimistic that this novel approach will provide a meaningful prolongation of survival for patients with relapsed or refractory lymphomas...
  11. ncbi request reprint Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center, University of Washington, and Aletheon Pharmaceuticals, Inc, Seattle, Washington 98109, USA
    Cancer Res 67:5921-8. 2007
    ..Improvements in tumor-to-normal organ ratios of radioactivity cannot be achieved using directly labeled Abs in combination but may be afforded by novel pretargeting methods...
  12. ncbi request reprint Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate
    Jostein Dahle
    Department of Radiation Biology, Norwegian Radium Hospital, Oslo, Norway
    Blood 110:2049-56. 2007
    ..Thorium-227 based constructs may provide a novel approach for targeted therapy against a wide variety of cancers...
  13. ncbi request reprint Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
    Biol Blood Marrow Transplant 12:697-702. 2006
    ..The rationale for incorporation of radioimmunotherapy into reduced intensity allogeneic transplantation regimens for non-Hodgkin lymphoma is discussed, as are current study designs, preliminary results, and future directions...
  14. pmc Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
    Anastasia Pantelias
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Blood 109:4980-7. 2007
    ..This study highlights the importance of screening the antigenic expression on lymphomas to select the optimal reagent for PRIT...
  15. ncbi request reprint High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98195, USA
    J Clin Oncol 25:1396-402. 2007
    ..Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites while limiting exposure to normal organs and may be particularly suited for older adults requiring high-dose therapy...
  16. pmc Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz
    John A Thompson
    Puget Sound Oncology Consortium, Seattle, WA, USA
    Blood 111:4048-54. 2008
    ..Posttransplantation IL-2 given at this dose and schedule of administration had no significant effect on PFS or OS. This study is registered at www.clinicaltrials.gov as NCT00002649...
  17. pmc Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
    John M Pagel
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 111:2261-8. 2008
    ..These data suggest that anti-CD45 PRIT using an anti-CD45-SA conjugate in a syngeneic murine model of disseminated leukemia may be more effective and less toxic than directly labeled monoclonal antibodies...
  18. pmc High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
    Cancer 113:1344-50. 2008
    ..We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients...
  19. doi request reprint Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma
    Franz Buchegger
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Oncologist 13:657-67. 2008
    ....
  20. pmc Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    Brian G Till
    Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 112:2261-71. 2008
    ..These results show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach. This trial was registered at www.clinicaltrials.gov as #NCT00012207...
  21. pmc Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA
    Blood 112:830-5. 2008
    ....
  22. doi request reprint Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies
    Eneida R Nemecek
    Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA
    Cancer Biother Radiopharm 23:181-91. 2008
    ..We examined an "extracorporeal adsorption therapy" (ECAT) method to remove circulating unbound radioimmunoconjugate and improve the ratios of radiation delivered to B-cells in a macaque model...
  23. pmc Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma
    Brian G Till
    Clinical Research Division of Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 49:1062-73. 2008
    ....
  24. doi request reprint Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose
    Joseph G Rajendran
    Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 49:837-44. 2008
    ..The goal of each approach is to deliver maximal myeloablative amounts of radioactivity within the tolerance of critical normal organs...
  25. ncbi request reprint A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies
    Yukang Lin
    The Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Cancer Res 66:3884-92. 2006
    ..These promising results have prompted large-scale cGMP production of the BC8 fusion protein for clinical trials to be conducted in patients with hematologic malignancies...
  26. pmc Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, the Univerisity of Washington, Seattle, WA 98109, USA
    Blood 108:328-36. 2006
    ..More than 90% of lymphomabearing mice could be cured with minimal toxicity using either reagent followed by 1200 muCi (44.4 MBq) 90Y-DOTA-biotin...
  27. ncbi request reprint Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates
    Craig Beeson
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Bioconjug Chem 14:927-33. 2003
    ..These studies demonstrate that the cleavable RIC substrate is able to bind to tumor antigens and localize within human tumor xenografts and that accelerated systemic clearance can be induced with beta-lactamase...
  28. ncbi request reprint Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133
    Patricia A Ganz
    University of California, Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 21:3512-9. 2003
    ....
  29. ncbi request reprint High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis
    Ajay K Gopal
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    Blood 102:2351-7. 2003
    ..076 at 8 years in the HD-RIT group and.086 at 7 years in the C-HDT group. HD-RIT may improve outcomes versus C-HDT in patients with relapsed FL...
  30. ncbi request reprint Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective
    Oliver W Press
    Division of Medical Oncology, University of Washington Medical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Semin Oncol 30:10-21. 2003
    ..This latter strategy has yielded complete remissions in the majority of treated patients, some durable for more than 5 years...
  31. ncbi request reprint Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts
    Krishnan Subbiah
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Nucl Med 44:437-45. 2003
    ..This study compared the immunoscintigraphy, toxicity, and therapeutic efficacy of pretargeted RIT with conventional RIT using an anti-CD20 antibody...
  32. ncbi request reprint Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle 98109, USA
    Blood 101:2340-8. 2003
    ..These lymphoma xenograft data suggest that pretargeted radioimmunotherapy using either anti-CD20 or anti-CD45 conjugates is highly effective and minimally toxic...
  33. ncbi request reprint A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex
    Chantal A Lackey
    Department of Bioengineering, University of Washington, Seattle, Washington 98195, USA
    Bioconjug Chem 13:996-1001. 2002
    ..The striking enhancement of protein delivery to the cytoplasm by complexed PPAAc suggests that this polymer could provide a new delivery agent for therapeutic, vaccine, and diagnostics development...
  34. ncbi request reprint Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin
    D Scott Wilbur
    Department of Radiation Oncology, University of Washington, Seattle 98195, USA
    Bioconjug Chem 13:611-20. 2002
    ..Although the differences in the two modified rSAv are not substantial, succinylated rSAv appears to have more favorable properties for pretargeting studies...
  35. ncbi request reprint A streptavidin-biotin binding system that minimizes blocking by endogenous biotin
    Kevin J Hamblett
    Department of Bioengineering, University of Washington, Seattle 98195, USA
    Bioconjug Chem 13:588-98. 2002
    ....
  36. ncbi request reprint Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism
    Ajay K Gopal
    Seattle Cancer Care Alliance, Mailstop G6 800, Rm 6802, University of Washington, 825 Eastlake Ave E, Seattle, 98109, USA
    Blood 103:3516-20. 2004
    ..05). These results establish the efficacy of 4HPR/rituximab combinations, confirm their caspase-mediated mechanism of action, and offer the potential for disease control with minimal toxicity for patients with B-cell malignancies...
  37. ncbi request reprint Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes
    Jinjuan Wang
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Mol Ther 9:577-86. 2004
    ..In view of these promising findings, a Phase I clinical trial for relapsed follicular lymphoma is being initiated...
  38. pmc 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center D5 380, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109, USA
    Blood 107:2184-91. 2006
    ..39-1.08; P = .09). The addition of targeted hematopoietic irradiation to conventional BU/CY is feasible and well tolerated, and phase 2 results are sufficiently encouraging to warrant further study...
  39. ncbi request reprint New treatment options have changed the survival of patients with follicular lymphoma
    Richard I Fisher
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
    J Clin Oncol 23:8447-52. 2005
    ..However, multiple new treatment options have been developed in the last decade, and their impact on survival of follicular lymphoma remains unknown...
  40. ncbi request reprint Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center Department of Medicine, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 11:4857-66. 2005
    ..Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is a transmembrane enzyme critical for the biosynthesis of phosphoglycerides whose product, phosphatidic acid, plays a key role in raf and AKT/mTor-mediated signal transduction...
  41. ncbi request reprint Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
    Herschel Wallen
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Ave N, D3 100, Seattle, WA 98109, USA
    J Clin Oncol 23:3439-46. 2005
    ..To evaluate outcomes of ablative allogeneic hematopoietic cell transplantation (HCT) in older patients with hematologic malignancies...
  42. ncbi request reprint Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
    John M Bennett
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Blood 105:4576-82. 2005
    ..With a median follow-up approaching 5 years, no case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treated patients)...
  43. ncbi request reprint Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model
    Eneida R Nemecek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Clin Cancer Res 11:787-94. 2005
    ..We evaluated the organ localization of yttrium-90-labeled anti-CD45 ((90)Y-anti-CD45) antibody in macaques, a model that had previously predicted iodine-131-labeled anti-CD45 ((131)I-anti-CD45) antibody biodistribution in humans...
  44. ncbi request reprint Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma
    Kevin J Hamblett
    Department of Bioengineering, Medicine, University of Washington, Seattle, Washington 98195, USA
    Bioconjug Chem 16:131-8. 2005
    ....
  45. ncbi request reprint High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes
    Joseph G Rajendran
    Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 45:1059-64. 2004
    ..This study demonstrates the feasibility of using CT to adjust for actual organ volumes in calculating organ-specific absorbed dose estimates...
  46. ncbi request reprint High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
    Ajay K Gopal
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
    Blood 99:3158-62. 2002
    ..High-dose treatment with (131)I-Tositumomab, etoposide, and cyclophosphamide results in a high remission rate and may provide long-term disease-free survival for patients with relapsed or refractory mantle cell lymphoma...
  47. pmc Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane
    Scott E James
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Immunol 180:7028-38. 2008
    ....
  48. ncbi request reprint Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy
    Joel B Epstein
    Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, University of Illinois at Chicago, 801 S Paulina Street, Room 556, Chicago, IL 60612 7213, USA
    Support Care Cancer 12:517-25. 2004
    ..The effectiveness of amphotericin B oral suspension versus nystatin oral suspension for the prevention of oral colonization by Candida in hematopoietic cell transplant (HCT) patients was examined...

Research Grants25

  1. Bispecific Antibody Engineering for AML RIT
    OLIVER W contact PRESS; Fiscal Year: 2010
    ..We anticipate that this approach will cure more patients and cause fewer toxicities than currently available therapies. ..
  2. PRETARGETING RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 2006
    ..We anticipate rapid translation of the results of these preclinical experiments into our clinical RIT program for human Non-Hodgkin's lymphomas. ..
  3. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver Press; Fiscal Year: 2007
    ..We anticipate rapid translation of the results of these preclinical experiments into our clinical RIT program for human AML. ..
  4. Anti-CD20 CTL for Therapy of Mantle Cell Lymphoma
    Oliver Press; Fiscal Year: 2007
    ..The preliminary results obtained to date suggest that this novel immunotherapy represents a safe, promising approach for patients with relapsed MCL. ..
  5. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver W Press; Fiscal Year: 2010
    ..This grant proposal describes the development of several innovations that markedly improve the effectiveness and decrease the toxicity of radiolabeled antibodies targeting the CD20 antigen on human B cell lymphomas. ..
  6. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver W Press; Fiscal Year: 2010
    ....
  7. PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS
    Oliver Press; Fiscal Year: 2001
    ..Rapid translation of the results of these preclinical experiments into active clinical radioimmunotherapy program for human non-Hodgkin's lymphomas is anticipated. ..
  8. Chimeric Anti CD20 T Cell Receptors for Lymphoma Therapy
    Oliver Press; Fiscal Year: 2003
    ....
  9. INTRACELLULAR TRAFFICKING OF IMMUNOTOXINS
    Oliver Press; Fiscal Year: 2003
    ....